Trends in alcohol withdrawal management by medical toxicologists in the acute care setting: an analysis of the Toxicology Investigators Consortium (ToxIC) Core Registry, 2016–2022
Alcohol and Alcoholism · 2025
DOI: 10.1093/alcalc/agaf047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alcohol and Alcoholism, 2025. Verfasst von John D DelBianco und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Toxicology, Department of Emergency and Hospital Medicine, Lehigh Valley Health Network/USF Morsani College of Medicine, 1200 S. …. Hauptthemen laut MEDLINE: Substance Withdrawal Syndrome, Toxicology. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Internal Grant Agency-Lehigh Valley Health Network Research Support Fund, CDC HHS, U.S. Food and Drug Administration.
Abstract (Originalsprache)
Aims
Alcohol withdrawal syndrome (AWS) requires urgent treatment to prevent morbidity and mortality. In the acute care setting, medical toxicologists play a critical role in AWS management, including the use of gamma-aminobutyric acid agonists and adjunctive medications. We aim to introduce the addiction medicine community to this role by describing clinical presentation and treatment of patients with AWS in the Toxicology Investigators Consortium Core Registry.
Methods
Medical toxicologists from participating sites enter demographic, exposure, clinical presentation, and treatment data on all patients they evaluate into the Core Registry. This was a secondary analysis of registry patients evaluated for AWS from 2016 to 2022. Data were coded in a spreadsheet and analyzed using descriptive statistics.
Results
We included 1093 cases. Agitation and delirium/toxic psychosis were documented in 373 (34.1%) and 227 (20.8%) patients, respectively. Benzodiazepines were the most common gamma-aminobutyric acid agonist treatment (n = 539, 49.3%). There was an overall decrease in the use of benzodiazepines alone and increases in the use of phenobarbital, ketamine, and dexmedetomidine. Intubation was performed in 115 (10.5%) patients. Naltrexone, used for alcohol use disorder, was given in 88 (8.1%) cases. The absolute number of AWS cases increased during this period.
Conclusions
Use of benzodiazepines alone to manage AWS decreased while phenobarbital, ketamine, and dexmedetomidine use increased. Many patients had severe withdrawal manifestations, and some received alcohol use disorder treatment, suggesting that medical toxicologists see more severe cases in the acute care setting and have an opportunity to address the underlying use disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Toxicology, Department of Emergency and Hospital Medicine, Lehigh Valley Health Network/USF Morsani College of Medicine, 1200 S. Cedar Crest Blvd., Allentown, PA 18103, United States.
- Department of Emergency and Hospital Medicine, Lehigh Valley Health Network/USF Morsani College of Medicine, 1200 S. Cedar Crest Blvd., Allentown, PA 18103, United States.
- Network Office of Research and Innovation, Lehigh Valley Health Network/USF Morsani College of Medicine, 1255 S. Cedar Crest Blvd., Suite 3200, Allentown, PA 18103, United States.
- Division of Trauma and General Surgery, Institute for Surgical Excellence, Lehigh Valley Health Network/USF Morsani College of Medicine, 1200 S. Cedar Crest Blvd., Allentown, PA 18103, United States.
Förderung
- Internal Grant Agency-Lehigh Valley Health Network Research Support Fund
- CDC HHS
- U.S. Food and Drug Administration
- Internal Grant Agency–Lehigh Valley Health Network Research Support Fund
- Centers for Disease Control and Prevention
Zitieren
APA
DelBianco, J. D., Galeano, K. J., Beauchamp, G. A., Surmaitis, R. M., Shara, S. E., Sutter, A., Kincaid, H., Stirparo, J. J., Wheel, K. L., Amaducci, A. M., & Toxicology Investigators Consortium (ToxIC) (2025). Trends in alcohol withdrawal management by medical toxicologists in the acute care setting: an analysis of the Toxicology Investigators Consortium (ToxIC) Core Registry, 2016–2022. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agaf047
Vancouver
DelBianco JD, Galeano KJ, Beauchamp GA, Surmaitis RM, Shara SE, Sutter A, et al. Trends in alcohol withdrawal management by medical toxicologists in the acute care setting: an analysis of the Toxicology Investigators Consortium (ToxIC) Core Registry, 2016–2022. Alcohol and Alcoholism. 2025. doi:10.1093/alcalc/agaf047
BibTeX
@article{DelBianco2025,
author = {DelBianco, John D and Galeano, Kira J and Beauchamp, Gillian A and Surmaitis, Ryan M and Shara, Stephanie E and Sutter, Alison and Kincaid, Hope and Stirparo, Joseph J and Wheel, Kathryn L and Amaducci, Alexandra M and Toxicology Investigators Consortium (ToxIC), Toxicology Investigators Consortium (ToxIC)},
title = {Trends in alcohol withdrawal management by medical toxicologists in the acute care setting: an analysis of the Toxicology Investigators Consortium (ToxIC) Core Registry, 2016–2022},
journal = {Alcohol and Alcoholism},
year = {2025},
doi = {10.1093/alcalc/agaf047}
}
EUVIMED